UNSW showcases the future of health
Summary
At UNSW, we are at the forefront of health translational research, but this can be difficult to see from the outside.This will be the first in a series of events purposefully designed to showcase UNSW capabilities aligned to each of the federal governments National Reconstruction Fund priority areas, giving government and industry an opportunity to learn more and to work with us.The expo is a wonderful opportunity for exhibitors to demonstrate their research in an interactive way such as a video, game, quiz, prototype, or virtual reality experience.The expo will demonstrate the breadth and depth of UNSWs translational research across:Future Health is the first of five planned events at UNSW this year aligned with the governments $15 billion National Reconstruction Fund. As part of the 10x Accelerator program, startups receive seed funding and 10 weeks of accelerated learning from experts and mentors.The best way to monitor a stroke patients recovery is via the continuous monitoring of their brain activity and blood flow, however there is currently no clinically approved technology for this, said Nuroflux Co-founder, CEO & CTO Sam van Bohemen.The current intensive and subjective nursing assessments are disruptive to patients and are a high operational burden to hospitals.Nuroflux is developing a medical device for the safe and passive monitoring of brain activity and blood flow in patients recovering from stroke. We have a particular passion for underserved communities, where a low-cost and portable device such as ours could have a significant positive impact, said Mr van Bohemen.Nuroflux participated in the UNSW Founders Health 10x Accelerator in 2021.Omico aims to improve access to next-generation treatments and preventive strategies for all Australians affected by cancer.Were a government-backed national network of leading researchers, clinicians and industry partners promoting precision medicine a game changer in the fight against cancer, Omico Chief Executive Officer and UNSW Conjoint Professor David Thomas said.Precision medicine uses a molecular view of each individuals cancer to identify the best possible treatments for them.In 2023 Omico partnered with UNSWs new Centre for Molecular Oncology (CMO) to deliver the national precision oncology program PrOSPeCT. The program provides 23,000 Australians impacted by cancer with free access to world-class genomic profiling, clinical assessment of their results and matching to advanced precision treatments available locally, including early-stage clinical trials.Were now offering precision oncology nationally to all who may benefit, said Prof. Thomas.Omico aims to bring the power of science to help patients and their doctors in their fight against cancer. It aims to do so through research-led care and in partnership with all stakeholders public and private who are critical to improving cancer outcomes.UNSW houses the Centre for Molecular Oncology, which provides the clinical infrastructure that enables national access to Omicos platforms and treatment programs.Admission to the expo on Thursday 14 March is free, however booking tickets is essential: https://www.eventbrite.com.au/e/unsw-future-health-expo-tickets-826297978497?aff=Media